The current state of immunotherapy for gliomas: an eye toward the future

PMID: 31473668
Journal: Journal of neurosurgery (volume: 131, issue: 3, J. Neurosurg. 2019 09;131(3):657-666)
Published: 2019-09-01

Authors:
Fecci PE, Sampson JH

ABSTRACT

The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.